Insulin sensitizers such as pioglitazone and GLP-1 receptor agonists have shown promise in improving liver histology and metabolic parameters in patients with NAFLD, although further research is needed to define their role in clinical practice [116]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.